Menu hamburgerclose


Zytoprotec Phase II Peritoneal Dialysis Study: Last Patient Out

Vienna, Europe, November 14, 2016 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids with cytoprotective properties, announced today that the last patient has completed treatment in a Phase II study with its lead product, PDprotec®. The Company expects results of this trial to be available in the first quarter of 2017.

> read more

Zytoprotec's Novel Dialysis Product Meets Both Endpoints in Phase II Study

Vienna, Europe, June 9, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today the highly promising outcome of the Phase II study of its peritoneal dialysis fluid PDprotec®. In this double-blind, placebo-controlled cross-over study, the two primary endpoints were successfully met.

> read more

FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid

Vienna, Europe, December 14, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to PDprotec®, the Company's peritoneal dialysis fluid for the treatment of patients with end-stage renal disease (kidney failure).

> read more

Neue Therapieansätze für eine Verbesserung der Bauchfelldialyse

Christian Doppler Labor „Molekulare Stressforschung in der Peritonealdialyse“ an der MedUni Wien eröffnet – Förderung durch Wissenschafts-, Forschungs- und Wirtschaftsministerium

> read more

Zytoprotec geht mit neuer Geschäftsführung in Entwicklungs-Endspurt

 Zwei Industrie-Veteranen mit erfolgreichen Karrieren in Biotech-Finanzierung und Medizinprodukte-Vertrieb gewonnen.

> read more